Clinical trials: Anlotinib
Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma
The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma
This phase II trial studies how well anlotinib hydrochloride works in treating patients with metastatic pheochromocytoma or paraganglioma.
- Conditions
- Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma, Pheochromocytoma, Metastatic, Paraganglioma, Malignant
- Trial name
- NCT04860700
- Testing
- anlotinib hydrochloride
- Where
- China
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Non-small Cell Lung Cancer
Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer
This study aims to explore the efficacy of Anlotinib with or without Immune Checkpoint Inhibitor in Standard Chemo-immunotherapy Failed Advanced NSCLC.
- Trial name
- ATHENA (NCT04322617)
- Testing
- Anlotinib plus the same Immune Checkpoint Inhibitors., Anlotinib plus the new Immune Checkpoint Inhibitors., Anlotinib
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Hunan Province Tumor Hospital
SCLC, Maintenance Treatment
Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell
This is a randomized, open, multicenter Phase III clinical study. A total of 136 participants are planned to be enrolled and randomly assigned to either the experimental group (platinum+etoposide → toripalimab plus anlotinib) or…
- Trial name
- SCLC (NCT06441344)
- Testing
- Toripalimab plus Anlotinib, Toripalimab
- Volunteers
- 136 people
- Sponsor
- Taizhou Hospital
Hepatocellular Carcinoma
A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)
This is a multi-center,open-label study to evaluate the efficacy and safety of anti-PD-1 antibody AK105 plus anlotinib hydrochloride in the first-line treatment of patients with unresectable hepatocellular carcinoma.
- Trial name
- NCT04172571
- Testing
- AK105, Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Akeso
Locally Advanced Esophageal Squamous Cell Carcinoma
Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
The goal of this clinical trial is to learn if cadonilimab combined with anlotinib can be a safe and effective neoadjuvant therapy in patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC).
- Trial name
- NCT06426797
- Testing
- Cadonilimab plus anlotinib
- Volunteers
- 25 people
- Sponsor
- Peking University People's Hospital
Pancreatic Neoplasms
A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer.
It is a trial to assess the efficacy and safety of Penpulimab and Anlotinib in Combination With Nab-paclitaxel Plus Gemcitabine as first-line Therapy in Patients (Pts) With Metastatic Pancreatic Cancer.
- Trial name
- PAAG (NCT05493995)
- Testing
- Penpulimab, Anlotinib, Nab paclitaxel
- Where
- China
- Volunteers
- 66 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Immunotherapy Gastroesophageal Junction
The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction
To evaluate the efficacy and safety of tislelizumab combined with antilotinib and SOX regimen for neoadjuvant treatment of locally advanced esophagogastric junction cancer
- Trial name
- NCT06396585
- Testing
- Tislelizumab, Anlotinib, Oxaliplatin
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Fujian Cancer Hospital
Colorectal Cancer, Immunotherapy
Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)
This study is designed to evaluate the efficacy and safety of the combination of Anlotinib and Sintilimab in advanced colorectal cancer as first-line treatment.
- Conditions
- Colorectal Cancer, Immunotherapy, Anlotinib, Sintilimab
- Trial name
- NCT04271813
- Testing
- Anlotinib plus Sintilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Changzheng Hospital
Non Small Cell Lung Cancer
Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients
This is a Phase I exploratory study. The study is divided into two parts (A/B).In part A, the primary endpoint is the determination of the recommended phase 2 dose (RP2D).
- Trial name
- NCT04967079
- Testing
- Trametinib, Anlotinib
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Shanghai Chest Hospital
Cervical Cancer
Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer
The goal of this clinical trial is to test a new treatment combination including cadonilimab, anlotinib and granulocyte-macrophage colony-stimulating factor (GM-CSF) in recurrent, metastasis and persistent cervical cancer.
- Trial name
- NCT05817214
- Testing
- Cadonilimab, Anlotinib, Granulocyte-Macrophage Colony-Stimulating Factor
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Zhongnan Hospital
Thyroid Neoplasms
Clinical Efficacy of 125I Brachytherapy Combined With Anlotinib in Radioiodine Refractory Thyroid Carcinoma Patients
A retrospective analysis was conducted on patients with radioiodine-refractory thyroid carcinoma (RRTC) who underwent radioactive 125I seed implantation combined with anlotinib from January 2019 to October 2024 at Jiangxi Cancer…
- Trial name
- NCT06367010
- Testing
- Iodine-125 brachytherapy combine with Anlotinib
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Advanced NSCLC
A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy
Immune resistance after treatment, there is no standard treatment, one of the most important and the most effective measures is immune to combination therapy。Targeted angiogenesis therapy has always been the focus of research on…
- Trial name
- NCT06356675
- Testing
- Tislelizumab, Anlotinib
- Volunteers
- 33 people
- Sponsor
- The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine
Neoadjuvant Therapy, Esophageal Squamous Cell Carcinoma
A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
The goal of this interventional study is to compare the safety and efficacy of neoadjuvant immunotherapy plus chemotherapy and anlotinib versus immunotherapy combined with concurrent chemoradiotherapy in the treatment of locally…
- Trial name
- NCT06354530
- Testing
- anlotinib, Thoracic radiotherapy
- Where
- China
- Volunteers
- 266 people
- Sponsor
- Army Medical Center of PLA
Lung Cancer Non-small Cell Stage IV
A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer
This is a phase III , randomized, double-blinded, multicenter clinical study to compare efficacy and safety of AK105 (Anti-PD1 antibody) combined with Carboplatin and Pemetrexed vs Placebo combined with Carboplatin and Pemetrexed…
- Trial name
- NCT03866980
- Testing
- AK105, carboplatin, pemetrexed
- Where
- 2 sites in China
- Volunteers
- 164 people
- Sponsor
- Akeso
Non-small Cell Lung Cancer
Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer
In recent years, with the emergence and clinical application of anti-angiogenesis therapy, the therapeutic effect of patients has been significantly improved while ensuring that the adverse reactions of patients do not increase.
- Trial name
- NCT06341530
- Testing
- anlotinib combined with penpulimab
- Where
- China
- Volunteers
- 33 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Breast Cancer
A Real-world Efficacy and Safety Study of Amlotinib for HER2-negative Advanced Breast Cancer
This study analyses the efficacy and safety of amlotinib as a study drug in the treatment of HER-2 negative advanced breast cancer in the real world, including the number of treatment lines, monotherapy, combination therapy, and…
- Trial name
- NCT06340165
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 153 people
- Sponsor
- The First Hospital of Jilin University
Melanoma
Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure
This study is an open-label, multicenter, single-arm Phase II clinical study to evaluate the effectiveness of cadonilimab (AK104) in combination with anlotinib in the treatment of locally advanced or metastatic melanoma.
- Trial name
- NCT06327698
- Testing
- Cadonilimab, anlotinib
- Volunteers
- 30 people
- Sponsor
- Hunan Cancer Hospital
Non-small Cell Lung Cancer
Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI
This study was designed to evaluate the efficacy and safety of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) in combination with pemetrexed and anlotinib for treatment of elderly patients with T790M-negative advanced…
- Trial name
- NCT06277674
- Testing
- Cadonilimab plus Pemetrexed and Anlotinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Guangzhou University of Traditional Chinese Medicine
Gastric Cancer
TAS-102 and Anlotinib in ≥3 Lines mGC
To determine the efficacy and safety of TAS-102 and Anlotinib in patients with metastatic gastric cancer who had been treated with ≥ 2 lines of prior standard chemotherapy
- Trial name
- NCT05029102
- Testing
- TAS 102, Anlotinib
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Zhejiang University
Metastatic Castration-resistant Prostate Cancer (CRPC)
Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer
In this study, we propose to use the combination of ET-SPACE NIR irradiation whole-body thermal stimulation, ICI (Tislelizumab), and RTK inhibitor (Anlotinib) in the multimodal treatment of CRPC.
- Trial name
- NCT06249750
- Testing
- Immunotherapy, Targeted therapy, Hyperthermia
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Pengyuan Liu